Diabetic Neuropathy: Clinical Trials

14 trials for Diabetic Neuropathy, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

9 completed, 3 unknown, 1 recruiting, 1 withdrawn. 14 Phase 3, 4 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 314Completed 9, Unknown 3, Recruiting 1, Withdrawn 1
Phase 24Completed 3, Withdrawn 1

Follow Diabetic Neuropathy: new trials by email Literature Review of Diabetic Neuropathy trials Research Report on Diabetic Neuropathy

Trials (filtered) newest first · largest first

All 14 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Extended-release Pregabalin for the Treatment of Neuropathic Pain in Patients With Diabetic Peripheral Neuropathy and Postherpetic Neuralgia
Experimental: Pregabalin XR, Comparator: Dorene Tabs, Comparator placebo - Diabetic Neuropathy, Neuropathic Pain
Phase 3RecruitingBrainfarma Industria Química e Farmacêutica S/A3482026-06-182026-07-20
Efficacy and Safety of KW21052 Compared to Lyrica in the Diabetic Patients With Neuropathic Pain
KW21052, Lyrica, Lyrica (low dose) - Diabetic Neuropathy
Phase 3UnknownKunWha Pharmaceutical Co., Ltd.3942013-08-012013-05-29
Neuroprotection by Tocotrienols in Type 1 and Type 2 Diabetes Mellitus
Tocotrienol, Placebo - Diabetic Neuropathy, Cognitive Impairment
Phase 3CompletedUniversiti Sains Malaysia3002011-06-012017-05-04
The Evaluation of Safety and Efficacy of JWHGWT on Diabetic Neuropathy
placebo, JWHGWT - Diabetic Neuropathy
Phase 3UnknownTaichung Veterans General Hospital1202008-07-012009-06-18
Diabetic Neuropathy Topical Treatment
ketamine, vehicle gel, ketamine + clonidine - Diabetic Neuropathy, Pain
Phase 3UnknownIrmandade da Santa Casa de Misericordia de Sao Paulo2002008-04-012008-04-18
An Evaluation of the Efficacy and Safety of E2007 in Patients With Painful Diabetic Neuropathy
Placebo, E2007 (2 mg), E2007 (4 mg) - Diabetic Neuropathy
Phase 2 / Phase 3CompletedEisai Inc.3522007-06-012014-07-11
A Safety and Efficacy Study for Tapentadol (CG5503) Extended Release for Patients With Painful Diabetic Peripheral Neuropathy
CG5503, placebo - Diabetic Neuropathy
Phase 3CompletedJohnson & Johnson Pharmaceutical Research & Development, L.L.C.3952007-04-012013-07-19
Safety and Efficacy of Dextromethorphan and Quinidine in the Treatment of the Pain of Diabetic Neuropathy
Neurodex - Pain, Diabetic Neuropathy
Phase 3CompletedAvanir Pharmaceuticals4502005-07-012016-07-14
A Study of Sativex® for Pain Relief Due to Diabetic Neuropathy
Sativex, Placebo - Pain, Diabetic Neuropathy
Phase 3CompletedJazz Pharmaceuticals2972005-07-012023-05-03
Effects of Pulsatile Intravenous Insulin Delivery on Diabetic Neuropathy in pATIENTS (Pts) With Type 1 and Type 2 Diabetes
Placebo, Pulsatile IV insulin delivery (humalog, humulin, novolog) - Diabetic Neuropathy
Phase 2 / Phase 3WithdrawnFlorida Atlantic University2005-02-012016-08-10
Safety and Efficacy of AS-3201 in the Treatment of Diabetic Sensorimotor Polyneuropathy
ranirestat, (AS-3201) - Diabetic Neuropathy
Phase 3CompletedSumitomo Pharma Co., Ltd.5002004-10-012008-01-14
A Follow-On Trial to Assess the Long Term Safety and Efficacy of SPM 927 in Painful Distal Diabetic Neuropathy
lacosamide - Diabetic Neuropathy
Phase 2 / Phase 3CompletedUCB Pharma4512004-09-012018-07-17
A Trial to Assess the Efficacy and Safety of SPM 927 in Subjects With Painful Distal Diabetic Neuropathy
SPM 927 - Diabetic Neuropathy
Phase 2 / Phase 3CompletedUCB Pharma4962004-04-012014-09-22
A Trial to Assess the Efficacy and Safety of SPM 927 (Lacosamide) in Subjects With Painful Distal Diabetic Neuropathy
SPM 927 - Diabetic Neuropathy
Phase 3CompletedUCB Pharma3572003-12-012014-09-22

Narrower conditions

Diabetic Neuropathies (14)  ·  Neuralgia (3)  ·  Pain (3)  ·  Peripheral Nervous System Diseases (2)  ·  Cognitive Dysfunction (1)  ·  Diabetes Complications (1)  ·  Hypoglycemia (1)  ·  Neuralgia, Postherpetic (1)  ·  Polyneuropathies (1)

Broader conditions

Diabetes Mellitus (14)  ·  Endocrine System Diseases (14)  ·  Nervous System Diseases (14)  ·  Neuromuscular Diseases (14)  ·  Diabetes Complications (13)  ·  Peripheral Nervous System Diseases (12)  ·  Neurologic Manifestations (5)  ·  Pathological Conditions, Signs and Symptoms (5)  ·  Signs and Symptoms (5)  ·  Pain (2)  ·  Cognition Disorders (1)  ·  Glucose Metabolism Disorders (1)  ·  Mental Disorders (1)  ·  Metabolic Diseases (1)  ·  Neurocognitive Disorders (1)

Interventions

2-(acetylamino)-3-methoxy-N-(phenylmethyl)-, (2R)- (3)  ·  Clonidine (1)  ·  Insulin Aspart (1)  ·  Insulin Lispro (1)  ·  Insulin, Regular, Human (1)  ·  Ketamine (1)  ·  Lacosamide (1)  ·  Pregabalin (1)  ·  Tapentadol (1)  ·  Tocotrienols (1)  ·  nabiximols (1)  ·  perampanel (1)  ·  ranirestat (1)

Sponsors

UCB Pharma (3)  ·  Avanir Pharmaceuticals (1)  ·  Brainfarma Industria Química e Farmacêutica S/A (1)  ·  Eisai Inc. (1)  ·  Florida Atlantic University (1)  ·  Irmandade da Santa Casa de Misericordia de Sao Paulo (1)  ·  Jazz Pharmaceuticals (1)  ·  Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (1)  ·  KunWha Pharmaceutical Co., Ltd. (1)  ·  Sumitomo Pharma Co., Ltd. (1)  ·  Taichung Veterans General Hospital (1)  ·  Universiti Sains Malaysia (1)

Countries

United States (5)  ·  Brazil (2)  ·  Canada (1)  ·  Germany (1)  ·  Malaysia (1)  ·  South Korea (1)  ·  Taiwan (1)  ·  United Kingdom (1)

Top investigators

Antonio Laurenza, M.D. (1)  ·  Betty Tuller, PhD (1)  ·  Chia-I Tsai, master (1)  ·  Judymara L Gozzani, Investigator (1)  ·  Kah Hay Yuen, PhD (1)  ·  Kwang-Kuk Kim, M.D., Ph.D. (1)  ·  Mariana Ferreira, Sports Nutrition (1)  ·  Solomon Tesfaye, JCHMT FRCP (1)

Results publications

PMID 18619874, PMID 19366965, PMID 19454870, PMID 20067958, PMID 21162697, PMID 22314263, PMID 23340531, PMID 29379943, PMID 35587172